The problems with it were well documented. The oil is thick, strongly scented, and deeply unpleasant to consume. Patients given it orally frequently vomited, and the nausea was so severe that sustained oral treatment was difficult to maintain. When physicians tried injecting it directly, the oil’s viscosity caused it to pool under the skin rather than disperse, forming painful blisters and abscesses at injection sites. The body couldn’t absorb it properly, and so the active compounds — whatever they were — never reached systemic circulation at useful concentrations. Some physicians tried mixing it with other substances to thin it; others experimented with direct skin application. None of these approaches produced reliable results.
The active compounds in chaulmoogra oil are fatty acids, chiefly chaulmoogric acid and hydnocarpic acid, with related compounds from the same chemical family. These are unusual fatty acids distinguished by a cyclopentenyl ring in their carbon chain structure — a feature that makes them chemically distinct from the more common straight-chain fatty acids found in most vegetable oils. That structural peculiarity was relevant to the difficulty of making the oil medically useful, though the full understanding of why came only incrementally.
What physicians knew in 1914 was empirical: the oil seemed to have some effect against leprosy when it could be administered in sufficient quantities. What they needed was a form in which it could actually be administered. Harry T. Hollmann, a physician at the U.S. Public Health Service’s Leprosy Investigation Station in Hawaii, was one of those urgently looking for a solution. He brought the problem to the College of Hawaii’s chemistry department. And through that channel, it reached Alice Ball.
